We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Newly Identified Biomarkers Detect Subcortical Small-vessel Disease

By LabMedica International staff writers
Posted on 04 Apr 2022
Print article
Image: Dementia, which can be caused by buildup of toxic molecules, cause brain injury, loss of memory and decline in intelligence (Photo courtesy of 123rf.com)
Image: Dementia, which can be caused by buildup of toxic molecules, cause brain injury, loss of memory and decline in intelligence (Photo courtesy of 123rf.com)

Biomarkers have been identified that were able to differentiate between classical Alzeheimer’s disease and subcortical small-vessel disease (SSVD), which is the most common vascular cognitive disorder.

Since no disease-specific cerebrospinal fluid (CSF) biomarkers are available for SSVD, the aim of investigators at the University of Gothenburg (Sweden) was to identify such markers.

For this study, the investigators worked with 170 healthy controls and patients from the Gothenburg Mild Cognitive Impairment (MCI) study who had been clinically diagnosed with SSVD dementia, Alzheimer's disease (AD), or mixed AD/SSVD. The investigators quantified CSF levels of amyloid-beta (Abeta)x-38, Abetax-40, Abetax-42, as well as soluble amyloid precursor protein (sAPP)-alpha and sAPP-beta.

Results revealed that sAPP-beta was lower in SSVD patients than in AD patients and controls. Receiver-operating characteristic (ROC) analyses showed that sAPP-beta moderately separated SSVD from AD and controls. Moreover, the CSF/serum albumin ratio was elevated exclusively in SSVD and could moderately separate SSVD from the other groups. These results showed that SSVD had a biomarker profile that differed from that of AD and controls, and to some extent also from mixed AD/SSVD, suggesting that signs of blood-brain barrier dysfunction and sAPP-beta could be additional tools to diagnose SSVD.

First author Dr. Petronella Kettunen, associate professor of neurobiology at the University of Gothenburg, said, “When we combined the biomarker for vascular injury with the protein fragment we identified, the potential for separating patients with subcortical small-vessel disease from control subjects, patients with Alzheimer’s disease, and patients with mixed dementia was improved. Up to now, we have had no markers for subcortical small-vessel disease, which means that the disease could not be easily identified by testing samples of spinal fluid or blood. We have now opened up an opportunity to identify the disease, enabling help for this patient group in the form of lifestyle changes and blood pressure-reducing medication.”

The SSVD study was published in the March 25, 2022, online edition of the journal Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring.

Related Links:
University of Gothenburg 

 

Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Lyme Disease Test
Lyme IgG/IgM Rapid Test Cassette
New
Multi-Function Pipetting Platform
apricot PP5

Print article

Channels

Immunology

view channel
Image: The findings were based on patients from the ADAURA clinical trial of the targeted therapy osimertinib for patients with NSCLC with EGFR-activated mutations (Photo courtesy of YSM Multimedia Team)

Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions

In the ongoing advancement of personalized medicine, a new study has provided evidence supporting the use of a tool that detects cancer-derived molecules in the blood of lung cancer patients years after... Read more

Microbiology

view channel
Image: Schematic representation illustrating the key findings of the study (Photo courtesy of UNIST)

Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours

Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.